METTL3 and melanoma: Wang et al. found that METTL3/14-deficient tumors increased cytotoxic tumor-infiltrating CD8+ T cells and elevated secretion of IFN-γ, CXCL9, and CXCL10 in the TME in vivo, and inhibition of METTL3/14 enhanced response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma (Wang et al., 2020).